ONCOassist

ONCOassist A revolutionary app designed by oncology professionals for oncology professionals. The go-to app for all oncology professionals.

It gives them comfort where they can access relevant, up to date tools and content at their fingertips. It is the only mobile-first platform that saves time and improves the quality of patient care for frustrated and under pressure oncology HCPs. With the advent of genomic sequencing, combined with an aging population, and new therapies. The decision-making process for oncology HCP's is becoming i

ncreasingly complex. Unfortunately, they have no easy access to the tools and information they need to make an informed decision quickly. This means they use multiple different software and tools to aid their decisions, many of which are not safe and validated. This wastes time & reduces the quality of patient care. We focus on making ONCOassist easily accessible to all oncology HCP’s by being available across multiple devices(iOS, Android, and Desktop) and ensuring safety through CE and FDA compliance. Such is the need for ONCOassist our community of users are actively engaging with us to help define our future tools based on their burning needs. ONCOassist is improving the delivery of cancer care globally and helping us to reach our goal of leveling the standard of care worldwide.

🚨 Latest 3 Update!🔷 SystImmune and Bristol Myers Squibb presented Phase III data for Izalontamab brengitecan (iza-bren...
05/06/2026

🚨 Latest 3 Update!

🔷 SystImmune and Bristol Myers Squibb presented Phase III data for Izalontamab brengitecan (iza-bren), an investigational EGFRxHER3 bispecific ADC, at ASCO 2026, demonstrating significant survival benefits in both triple-negative breast cancer (TNBC) and esophageal squamous cell carcinoma (ESCC).

🔷 In TNBC, median OS was 15.9 vs 12.5 months and median PFS was 8.5 vs 3.1 months versus chemotherapy. In ESCC, median OS was 9.8 vs 7.2 months and median PFS was 4.2 vs 2.0 months, supporting iza-bren's potential as a new treatment option across multiple difficult-to-treat cancers.

🔗 Read more: https://bit.ly/ONCOnews-04-Jun-05

🚨 Latest Update!🔷 Agilent received FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platf...
05/06/2026

🚨 Latest Update!

🔷 Agilent received FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric/gastroesophageal junction adenocarcinoma who may be eligible for treatment with Pembrolizumab (KEYTRUDA®).

🔷 The approval extends access to FDA-approved PD-L1 companion diagnostic testing across additional tumor types on a single automated platform, supporting streamlined pathology workflows and informed immunotherapy treatment decisions.

🔗 Read more: https://bit.ly/ONCOnews-04-Jun-04

05/06/2026

🏃 Exercise as Cancer Treatment?

One of the most interesting updates from ASCO 2026 wasn’t a new drug.

Dr. Shaqil Kassam highlights the CHALLENGE study, where a structured exercise program:
✅ Improved overall survival
✅ Remained highly cost-effective
✅ Could become part of routine colorectal cancer care

Sometimes the most impactful interventions aren’t
found in a pharmacy.

🚨 Latest 3 Update!🔷 AstraZeneca presented updated Phase III SERENA-6 results evaluating Camizestrant plus a CDK4/6 inh...
05/06/2026

🚨 Latest 3 Update!

🔷 AstraZeneca presented updated Phase III SERENA-6 results evaluating Camizestrant plus a CDK4/6 inhibitor in patients with HR-positive, HER2-negative advanced breast cancer who developed an emergent ESR1 mutation during first-line treatment.

🔷 The combination reduced the risk of disease progression or death by 55% (median PFS 16.8 vs 9.2 months; HR 0.45) and reduced the risk of second progression or death by 37% (median PFS2 25.7 vs 19.1 months; HR 0.63). Additionally, 51% of patients achieved ctDNA clearance versus 1.9% with standard of care, supporting the benefit of early treatment switching upon ESR1 mutation detection.

🔗 Read more: https://bit.ly/ONCOnews-04-Jun-03

🚨 Latest Update!🔷 The European Commission approved Nivolumab (Opdivo®) plus AVD for previously untreated Stage III/IV ...
05/06/2026

🚨 Latest Update!

🔷 The European Commission approved Nivolumab (Opdivo®) plus AVD for previously untreated Stage III/IV classical Hodgkin lymphoma (cHL) in adults and adolescents aged 12 years and older, marking the first immunotherapy-based frontline regimen approved for this setting in the EU.

🔷 The approval was based on the phase III SWOG 1826 trial, where Nivolumab plus AVD reduced the risk of disease progression or death by 58% versus brentuximab vedotin plus AVD (HR 0.42), demonstrating a significant progression-free survival benefit.

🔗 Read more: https://bit.ly/ONCOnews-04-Jun-02

🚨 Latest Update🔷 The U.S. FDA has approved FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for...
05/06/2026

🚨 Latest Update

🔷 The U.S. FDA has approved FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for TALZENNA® (Talazoparib) in combination with XTANDI® (Enzalutamide). The approval helps identify patients with HRR gene-mutated metastatic castration-resistant prostate cancer who may benefit from this targeted treatment approach.

🔷 This milestone highlights the growing importance of biomarker-driven care in advanced prostate cancer. Companion diagnostics continue to play a critical role in matching patients to the most appropriate precision medicine therapies.

🔗 Read more: https://bit.ly/ONCOnews-04-Jun-01

04/06/2026

🧬 ASCO 2026 Colorectal Cancer Update
Dr. Shaqil Kassam reviews the latest BREAKWATER Cohort 3 data in BRAF V600E metastatic colorectal cancer.

📊 Key finding:
The investigational arm combining Encorafenib + Cetuximab + FOLFIRI has not yet reached median overall survival, compared with 20 months for FOLFIRI alone.

💡 This may give clinicians greater flexibility when choosing between FOLFOX and FOLFIRI backbones.

04/06/2026

🚨 ASCO 2026 Breakthrough

Dr. Shaqil Kassam highlights what may be the most exciting data from ASCO 2026:

🧬 Daraxonrasib (RASolute-302)
📈 Improved OS, PFS & response rates
⏳ Median OS: 13.2 vs 6 months

Could this become the new standard of care for second-line pancreatic cancer?

🏆 We Have Our ONCO-IQ Quiz Cup Champion! 🏆After four days of intense competition and an incredibly close leaderboard, he...
04/06/2026

🏆 We Have Our ONCO-IQ Quiz Cup Champion! 🏆

After four days of intense competition and an incredibly close leaderboard, here are the winners of the ONCO-IQ Quiz Cup at the 2026 ASCO® Annual Meeting.

👑 ONCO-IQ Quiz Cup Champion
🥇 Dr. Sonam Gupta

🏅 Prize Winners
🥈 Dr. Mallika Dhanda
🥉 Giuseppe Ippolito

👏 Honourable Mentions
• Dr. Jorge Soriano Lorenzo
• Dr. Luis Gabriel Parra Lara
• Dr. Stanley Ozogbo

A huge congratulations to all our winners and participants. The competition showcased outstanding oncology knowledge, with many leaderboard positions separated by the narrowest of margins.

Thank you to everyone who took part in the ONCO-IQ Quiz Cup and helped make it such an exciting and engaging experience throughout ASCO 2026.

We look forward to bringing more opportunities for learning, competition, and collaboration to the global oncology community.

🚨 Latest Update!🔷 Avenzo Therapeutics presented updated Phase I/II data for AVZO-021, a selective CDK2 inhibitor, at A...
03/06/2026

🚨 Latest Update!

🔷 Avenzo Therapeutics presented updated Phase I/II data for AVZO-021, a selective CDK2 inhibitor, at ASCO 2026 in heavily pretreated patients with HR-positive/HER2-negative breast cancer, an area of significant unmet need following CDK4/6 inhibitor therapy.

🔷 Across all monotherapy doses, median PFS was 5.3 months with a median follow-up of 8.4 months, while the therapy demonstrated encouraging clinical activity and a favorable tolerability profile, supporting its continued development in combination strategies.

🔗 Read more: https://bit.ly/ONCOnews-03-Jun-05

Address

3rd Floor, 41/42, High Street
Killarney
V93T8K7

Website

Alerts

Be the first to know and let us send you an email when ONCOassist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ONCOassist:

Shortcuts

Share

Category